And though the idea is tricky, commercializing our genome is no longer about "hey, the next R&D breakthrough will come from your genome." It's about making sure that the first humans to create such breakthroughs can get rich off the money it pays for them.

This is why it's so important that companies refrain from selling our genomes to biotech companies.